Cartesian Therapeutics 8/8/2024 Earnings Report $12.58 -0.61 (-4.59%) As of 03:39 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Cartesian Therapeutics EPS ResultsActual EPS$0.54Consensus EPS -$0.81Beat/MissBeat by +$1.35One Year Ago EPSN/ACartesian Therapeutics Revenue ResultsActual Revenue$33.45 millionExpected Revenue$6.00 millionBeat/MissBeat by +$27.45 millionYoY Revenue GrowthN/ACartesian Therapeutics Announcement DetailsQuarterDate8/8/2024TimeBefore Market OpensConference Call ResourcesPress ReleaseRNAC Earnings HistoryPowered by Remove Ads Cartesian Therapeutics Earnings HeadlinesCartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceApril 1 at 7:00 AM | globenewswire.comSubstantial Insider Buying: American Express, Asana, and MoreMarch 30 at 11:16 AM | 247wallst.comA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same indicator that helped me call the bear market of 2018... the bull market in 2020... the bear market in 2022... the roaring bull markets in 2023 and 2024... and more. I'm convinced it has helped me identify the next big crash too. We are at an important juncture in the markets. Knowing what to do in the months to come is critical.April 1, 2025 | Chaikin Analytics (Ad)Timothy Springer Spends US$1.4m On Cartesian Therapeutics StockMarch 23, 2025 | finance.yahoo.comOppenheimer Reaffirms Their Hold Rating on Cartesian Therapeutics (RNAC)March 17, 2025 | markets.businessinsider.comCartesian Therapeutics, Inc.: Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business UpdateMarch 16, 2025 | finanznachrichten.deSee More Cartesian Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cartesian Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cartesian Therapeutics and other key companies, straight to your email. Email Address About Cartesian TherapeuticsCartesian Therapeutics (NASDAQ:RNAC), a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.View Cartesian Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio? Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
